Tagrisso was approved under a Priority Review based on the pivotal LAURA Phase III trial in adults with unresectable stage III epidermal growth factor receptor-mutated non-small cell lung cancer.
FDA Approves Tagrisso for Unresectable Stage III Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer
Tagrisso was approved under a Priority Review based on the pivotal LAURA Phase III trial in adults with unresectable stage III epidermal growth factor receptor-mutated non-small cell lung cancer.
